Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, AKEBIA THERAPEUTICS, INC. reported revenue of $236M, up 47.5% year over year. Operating margin was 9.9% and net margin -2.3%, on a free-cash-flow margin of 28.7% with capital expenditure at 0.1% of revenue. Every figure is computed directly from AKBA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $236M | 9.9% | -2.3% |
| FY2024 | $160M | -31.5% | -43.3% |
| FY2023 | $195M | -23.8% | -26.7% |
| FY2022 | $292M | -27.6% | -32.2% |
| FY2021 | $212M | -125.0% | -133.3% |
How does AKBA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: PG · JNJ · ABBV · BMY · ABT · AMGN
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.